Discovery of 2-Methyl-5-(1<i>H</i>-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M<sub>4</sub> mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders-Reference-Cited by-同舟云学术

Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M₄ mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders

Published:2024-07-18 Issue:15 Volume:67 Page:13286-13304
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liu Boqun¹,Thompson Geoff²,Jörg Manuela¹^ORCID,Barnes Nicholas²,Thal David M.²³^ORCID,Christopoulos Arthur²³⁴,Capuano Ben¹^ORCID,Valant Celine²³^ORCID,Scammells Peter J.¹^ORCID

Affiliation:

1. Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia

2. Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia

3. Australian Research Council Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

4. Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

Funder

National Health and Medical Research Council

Australian Research Council

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01207

Reference36 articles.

1. Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gsα and is not a consequence of phosphoinositidase C activation

2. Gq/11and Gi/oactivation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype

3. Biased Profile of Xanomeline at the Recombinant Human M₄ Muscarinic Acetylcholine Receptor

4. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function

5. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases